Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

The monoclonal antibody trastuzumab (Herceptin®), which targets the human epidermal
growth factor receptor 2 (HER2), is approved for the treatment of early breast and advanced …

Background In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy
with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

Biosimilars are increasingly available for the treatment of many serious disorders, however
some concerns persist about switching a patient to a biosimilar whose condition is stable …

Importance The high cost of biologics used to treat cancer has been an increasing burden in
the world. In China, the recent approval of cancer biosimilar drugs to resolve this problem is …

Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases
where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by …

Background: Patients with cancer who are treated with monoclonal antibodies are at risk for
developing infusion reactions. However, for some monoclonal antibodies, the incidence of …

Background The recommended preoperative approach for HER2-positive breast cancer is
unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen …

Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy
and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the …